J&J multiple myeloma drug succeeds in first-line combination study

(Reuters) – Johnson & Johnson’s blockbuster multiple myeloma drug Darzalex when added to a standard therapy regimen reduced the risk of disease progression or death by 50 percent compared with the standard therapy alone in patients not previously treated for the blood cancer, according to data released on Tuesday.


Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *